International Journal of Psychology and Psychiatry
  • Year: 2015
  • Volume: 3
  • Issue: 1

Clinical uses of Paroxetine: an underutilized drug by Physicians

  • Author:
  • Ranjan Bhattacharyya1, Barin Mallik2, Madhab Mandal3, Sumita Bhattacharyya4, Utpal Ray5, Bejoy Bikram Banerjee6
  • Total Page Count: 9
  • Page Number: 109 to 117

1Assistant Professor, Department of Psychiatry, Murshidabad Medical College & Hospital, Berhampore, West Bengal, India

2Assistant Professor, Department of Radiology, Murshidabad Medical College & Hospital, Berhampore, West Bengal, India

3RMO cum Cl Tutor, Department of General Medicine, Murshidabad Medical College & Hospital, Berhampore, West Bengal, India

4Senior Resident, Department of Dermatology, Institute of Post graduate Medical Education & Research, Kolkata, West Bengal, India

5Assistant Professor, Department of Anesthesiology, Murshidabad Medical College & Hospital, Berhampore, West Bengal, India

6Student, ESIC Medical College, Joka, Kolkata, West Bengal, India

Online published on 9 April, 2015.

Abstract

Paroxetine has been introduced in 1993 used for the treatment of depression, panic, anxiety, obsessive compulsive disorders (OCD) and other related disorders. Paroxetine has the strongest inhibition of serotonin uptake but is less specific than other SSRIs. The FDA approval in adult population are Major depressive disorder, obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. The systemic review with literatures about the clinical uses, pharmacokoinetic properties has been discussed. Its safety especially in paediatric population, various adverse effects, ACOG guidelines, FDA black box warnings are reviewed. Discontinuation reaction of Paroxetine and various adverse reactions are largely unknown to general practioners. In India this drug has been restricted to prescriptions of specialists only which limit the beneficial effects of this molecule to larger population. More awareness is required to extend benefits to general population as it is getting newer approval including use to reduce post menopausal hot flashes.